These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 32162815)

  • 1. Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis.
    Kim JJ; McFarlane T; Tully S; Wong WWL
    Oncologist; 2020 Mar; 25(3):e512-e519. PubMed ID: 32162815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.
    Ikeda S; Kudo M; Izumi N; Kobayashi M; Azuma M; Meier G; Pan J; Ishii M; Kaneko S
    Value Health Reg Issues; 2021 May; 24():82-89. PubMed ID: 33524900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
    Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
    Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
    Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Lenvatinib Compared with Sorafenib for the First-Line Treatment of Advanced Hepatocellular Carcinoma in Australia.
    Saiyed M; Byrnes J; Srivastava T; Scuffham P; Downes M
    Clin Drug Investig; 2020 Dec; 40(12):1167-1176. PubMed ID: 33140194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Lenvatinib in the Treatment of Advanced or Unresectable Hepatocellular Carcinoma from a Canadian Perspective.
    Meyers BM; Vogel A; Marotta P; Kavan P; Kamboj L; Pan J; Geadah M; Trueman D; Sabapathy S
    Can J Gastroenterol Hepatol; 2021; 2021():8811018. PubMed ID: 33681090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
    J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
    Cai H; Zhang L; Li N; Zheng B; Liu M
    J Comp Eff Res; 2020 Jun; 9(8):553-562. PubMed ID: 32419473
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenvatinib: A Review in Hepatocellular Carcinoma.
    Al-Salama ZT; Syed YY; Scott LJ
    Drugs; 2019 Apr; 79(6):665-674. PubMed ID: 30993651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
    Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
    J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
    Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
    Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
    Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
    Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
    Walton M; Wade R; Claxton L; Sharif-Hurst S; Harden M; Patel J; Rowe I; Hodgson R; Eastwood A
    Health Technol Assess; 2020 Sep; 24(48):1-264. PubMed ID: 33001024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
    Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
    Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
    Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
    J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis.
    Casadei-Gardini A; Scartozzi M; Tada T; Yoo C; Shimose S; Masi G; Lonardi S; Frassineti LG; Nicola S; Piscaglia F; Kumada T; Kim HD; Koga H; Vivaldi C; Soldà C; Hiraoka A; Bang Y; Atsukawa M; Torimura T; Tsuj K; Itobayashi E; Toyoda H; Fukunishi S; Rimassa L; Rimini M; Cascinu S; Cucchetti A
    Liver Int; 2021 Jun; 41(6):1389-1397. PubMed ID: 33547848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status of Conversion Hepatectomy After Sorafenib and Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Mimura T; Minami A; Momose K; Hirano H; Tanaka M; Ueda Y; Tai K; Yasuhara Y; Nakagawa D; Yamamoto A; Kido M; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2024 Jul; 44(7):3097-3103. PubMed ID: 38925835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
    Briggs A; Daniele B; Dick K; Evans TRJ; Galle PR; Hubner RA; Lopez C; Siebert U; Tremblay G
    Br J Cancer; 2020 Jun; 122(12):1754-1759. PubMed ID: 32265508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
    Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
    Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.